Physician profile
Nikiru J Ezeani
NPI 1790900868
$1,650.48
in general payments reported to CMS, 2019-2025
11 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $557 · 2023: $284 · 2024: $334 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $363.41 | 2023-2025 | Rexulti |
| Angiodynamics, INC. | $247.48 | 2022 | |
| Abbvie INC. | $211.13 | 2022-2024 | |
| Zealand Pharma US, INC. | $172.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $138.01 | 2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $125.01 | 2021 | |
| Neurocrine Biosciences, INC. | $114.48 | 2025 | |
| Janssen Products, LP | $102.30 | 2023 | Symtuza |
| Lilly USA, LLC | $98.30 | 2023-2024 | Mounjaro |
| Axsome Therapeutics, INC. | $60.95 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $16.87 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikiru Ezeani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.